While economies everywhere continue to face a global slowdown, investors should turn to the safety of stocks in a recession-proof sector, Jim Cramer said Tuesday on CNBC's "Mad Money." He cited Seattle Genetics as the perfect example of one such stock.
With a market capitalization of $2.4 billion, Seattle Genetics [SGEN 20.865 1.045 (+5.27%) ] is a small company, but Cramer thinks it’s worth speculating on.
The Bothell, Wash.-based firm champions the use of innovative biotechnology — like engineered antibodies to target and kill cancer cells while sparing healthy cells. And though the stock isn't profitable just yet, it does have one drug — Adcetris — already on the market and is expected to start raking in material revenues in 2014.
Cramer also noted that at the American Society of Clinical Oncology conference, Seattle Genetics released "bullish phase two data" about the use of Adcetris to treat other types of lymphoma, in addition to the Hodgkin's and large cell strains of lymphoma the drug has already successfully treated.
Clay did a great job - energetic, animated, clear and accurate, and he neatly avoided several potential traps and pitfalls. And, after staying long and strong over years of investing in SGEN, it's always nice to find validation of one's research and faith and resilience, regardless of the source.
But it's also important to keep in mind that Cramer is a know-nothing clown and he eventually can - and usually will - turn on you on a dime.
With all of that in mind, this was an incredibly bullish interview, and the affirmative exposure - as predicted - comes in the wake of the landmark NYTimes story of a few days ago.
To make it easier on others, here's the Cramer link: